RevBio secures NIH grant for game-changing TETRANITE Technology

RevBio, Inc., revealed that it has secured a substantial grant of up to $3.4 million, to be disbursed over the next three years, from the National Institute on Aging (NIA), a pivotal segment of the National Institutes of Health (NIH). The grant, provided through the Commercialization Readiness Program, is set to bolster the company’s late-stage product development endeavors and facilitate a pivotal clinical trial. The focus? To showcase the unparalleled safety and efficacy of their product against existing standards of care.

Unlocking the Potential of TETRANITE in Bone Healing

The research, fuelled by this grant, pivots on the unique abilities of the patented TETRANITE technology, aiming to redefine fracture treatments. TETRANITE showcases the prowess to fill bone gaps, secure bone fragments, and supercharge the healing process through its osteoconductive traits. The technology’s versatility allows it to play a dual role: serving as an intraoperative fixation aid and complementing traditional hardware fixation. This ensures optimal load distribution between bone and metal systems, fortifying stability and thus promoting optimal healing. Plus, the potential for TETRANITE to be injected minimally invasively, circumventing conventional open reduction internal fixation (ORIF) surgeries, presents a massive leap forward. Notably, this grant builds upon a previous $2 million SBIR Phase II grant, also from the National Institute on Aging.

R&D Insights & The Staggering Potential of TETRANITE

Brittany McDonough, RevBio’s R&D Program Manager, underlined the significant findings from their pre-clinical studies. She shared insights on how TETRANITE remarkably redistributes load from plates and screws, diminishing hardware failure risks. The technology also introduces a resorbable scaffold that expedites healing after traumatic injuries.

An Aging America & The Imperative for Better Fracture Treatments

With over 2.1 million fragility fractures reported annually in the U.S. – a figure projected to triple by 2040 due to an aging demographic – the need for innovative fracture treatments is pressing. Despite surgical advances, complications like nonunion, malunion, and hardware failure loom large, especially in the elderly. RevBio’s Orthopaedic Scientific Advisory Board member, Michael J. Weaver, MD, emphasized the transformative potential of TETRANITE in addressing these challenges.

Overall, with its promising technology and this monumental grant, RevBio is poised to redefine the landscape of fracture treatments and offer a brighter future for millions afflicted by bone injuries.